AACR logo

More articles from Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors
Andrew A. Davis, Wade T. Iams, David Chan, Michael S. Oh, Robert W. Lentz, Neil Peterman, Alex Robertson, Abhik Shah, Rohith Srivas, Timothy J. Wilson, Nicole J. Lambert, Peter S. George, Becky Wong, Haleigh W. Wood, Jason C. Close, Ayse Tezcan, Ken Nesmith, Haluk Tezcan, Young Kwang Chae

Molecular Cancer Therapeutics Jul 2020, 19 (7) 1486-1496; DOI: 10.1158/1535-7163.MCT-19-1060
A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer
Jing Yang, Kai Song, Wenbing Guo, Hailong Zheng, Yelin Fu, Tianyi You, Kai Wang, Lishuang Qi, Wenyuan Zhao, Zheng Guo

Molecular Cancer Therapeutics Jul 2020, 19 (7) 1497-1505; DOI: 10.1158/1535-7163.MCT-19-0864
Anti-KIT DNA Aptamer for Targeted Labeling of Gastrointestinal Stromal Tumor
Sudeep Banerjee, Hyunho Yoon, Mayra Yebra, Chih-Min Tang, Mara Gilardi, Jayanth S. Shankara Narayanan, Rebekah R. White, Jason K. Sicklick, Partha Ray

Molecular Cancer Therapeutics May 2020, 19 (5) 1173-1182; DOI: 10.1158/1535-7163.MCT-19-0959
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy
Vincenza Conteduca, Sheng-Yu Ku, Loredana Puca, Megan Slade, Luisa Fernandez, Judy Hess, Rohan Bareja, Panagiotis J. Vlachostergios, Michael Sigouros, Juan Miguel Mosquera, Andrea Sboner, David M. Nanus, Olivier Elemento, Ryan Dittamore, Scott T. Tagawa, Himisha Beltran

Molecular Cancer Therapeutics May 2020, 19 (5) 1157-1164; DOI: 10.1158/1535-7163.MCT-19-0926
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg, Jason Roszik, Anthony P. Conley, Alexander J. Lazar, Daniella E. Portal, David S. Hong, Aung Naing, Cynthia E. Herzog, Neeta Somaiah, Maria A. Zarzour, Shreyaskumar Patel, Robert E. Brown, Vivek Subbiah

Molecular Cancer Therapeutics May 2020, 19 (5) 1165-1172; DOI: 10.1158/1535-7163.MCT-19-0579
Oxaliplatin–DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy
Maike Zimmermann, Tao Li, Thomas J. Semrad, Chun-Yi Wu, Aiming Yu, George Cimino, Michael Malfatti, Kurt Haack, Kenneth W. Turteltaub, Chong-xian Pan, May Cho, Edward J. Kim, Paul T. Henderson

Molecular Cancer Therapeutics Apr 2020, 19 (4) 1070-1079; DOI: 10.1158/1535-7163.MCT-19-0133
Clinical Application of Next-Generation Sequencing–Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
Changhee Park, Miso Kim, Min Jung Kim, Hyeongmin Kim, Chan-Young Ock, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Jong-Il Kim, Dae Seog Heo

Molecular Cancer Therapeutics Mar 2020, 19 (3) 937-944; DOI: 10.1158/1535-7163.MCT-19-0457
Genomic and Expression Analyses Define MUC17 and PCNX1 as Predictors of Chemotherapy Response in Breast Cancer
Waleed S. Al Amri, Lisa M. Allinson, Diana E. Baxter, Sandra M. Bell, Andrew M. Hanby, Stacey J. Jones, Abeer M. Shaaban, Lucy F. Stead, Eldo T. Verghese, Thomas A. Hughes

Molecular Cancer Therapeutics Mar 2020, 19 (3) 945-955; DOI: 10.1158/1535-7163.MCT-19-0940
KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer
Song Ye, Xiaoge Hu, Chao Ni, Weiwei Jin, Yaping Xu, Lianpeng Chang, Huaixiang Zhou, Jiahong Jiang, Liu Yang

Molecular Cancer Therapeutics Mar 2020, 19 (3) 956-965; DOI: 10.1158/1535-7163.MCT-18-1385
Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Dina Cramer, Johanna Mazur, Octavio Espinosa, Matthias Schlesner, Daniel Hübschmann, Roland Eils, Eike Staub

Molecular Cancer Therapeutics Mar 2020, 19 (3) 927-936; DOI: 10.1158/1535-7163.MCT-19-0045

Main menu

User menu

Search

More articles from Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Pages

Articles

Info for

About MCT